Hello, Miljenko, (continued)
MK and other pipeline issues:
NXTR has some preliminary results from the Phase II trial for MK. NXTR tried to send the result out to a November meeting as 'late breaker (name?)', but was rejected for being too late. The full result will come out in 99Q1, and Phase III is expected in mid-99.
During the CC, one person asked the possibility of accelerating the trial, given the reduced burn rate from the spin-off. NXTR will not do that, according to Michael Hart.
No detail was mentioned for the MK trial, such as dosing, etc.
The current treatment for NX1838 is via injection. NXTR is trying a non-invasivie form of delivering the drug. If it can be done, it will be a huge positive for AMD, since the alternative will be either laser treatment or injection in the eyeballs. However, given NXTR's credit, I have to doubt if it can do it, at this moment.
NX-211 is in late clinic trial, and Phase I trial is going to be initiated in 99H1. [Do you know how good this drug is in non-liposome form?]
Shorts:
I do not mind the large short position. I do feel very concerned, however, when I do not know why the bears are shorting NXTR. Unlike the bears for BVF, ORG, NVX, etc, the shorts on NXTR seem to be rather quiet.
[Maybe, the majority of the shorts are the hedging for the convertables after all.]
Steven
ps: the phone number for the CC is 402-220-1030, and the playback will be availble to later today. |
